Purpose. To describe a case of postoperative scleritis caused by a novel strain of Nocardia resistant to linezolid and trimethoprim-sulfamethoxazole (TMP-SMX). Methods. Case report of a patient with microbiologically proven scleritis due to Nocardia asteroides. Results. The patient presented with pain, redness, and nodules on the sclera three months following pterygium excision with mitomycin C and amniotic membrane placement. As no response was noted with empiric treatment for bacterial scleritis, debridement was performed. The cytopathology report showed gram positive filamentous bacteria. A presumptive diagnosis of Nocardia scleritis was made and therapy was initiated based on a literature review on treatments for Nocardia infections. Cultures returned growing Nocardia asteroides. Antibiotic sensitivity testing revealed resistance to linezolid and TMP-SMX which are the traditional drugs of choice for Nocardia. The patient was treated with amikacin and imipenem as well as extensive debridement with pedicle grafts. The patient’s scleritis resolved with a good visual outcome. Conclusions. Cultures should be obtained in all cases of necrotizing scleritis in patients with a recent history of conjunctival surgery to rule out unusual organisms such as Nocardia. Although literature states that resistance to linezolid and TMP-SMX is rare in Nocardia, sensitivity testing can be useful in unresponsive cases.

1. Introduction
The bacterial genus Nocardia includes a number of species which are Gram positive, aerobic, and filamentous shaped. Nocardia species typically only cause disease in immunocompromised individuals; however, a number of Nocardia infections have been reported in the immunocompetent including pulmonary nocardiosis and ocular infections such as keratitis and scleritis. The current first line antimicrobial treatment in cases of Nocardia scleritis includes amikacin and/or trimethoprim-sulfamethoxazole (TMP-SMX) [1]. In refractory Nocardia infection, linezolid is typically the antimicrobial agent of choice, as it has demonstrated near 100% sensitivity [2–4]. Our case represents the first report of Nocardia scleritis with in vitro resistance to linezolid as well as the second reported case of a Nocardia scleritis with in vivo resistance to TMP-SMX.

2. Case
A 46-year-old female with no pertinent past medical history presented to the urgent eye clinic with complaints of right eye mass with pain, redness, and swelling which had progressed over 3-4 weeks. She also complained of blurring, flashing lights, and color swirling in that eye. She had undergone pterygium surgery with mitomycin C and amniotic membrane graft placement of her right eye 3 months prior to presentation.

On presentation, the patient was on an empirical treatment regimen of gatifloxacin ophthalmic drops four times a day (QID), prednisolone-acetate eye drops QID, and tobramycin-dexamethasone ophthalmic ointment QID. Initial examination showed inflamed, necrotic, and ischemic appearing sclera bordered by hyperemic and telangiectatic conjunctiva in the nasal quadrant (Figure 1). Uncorrected
visual acuity was 20/20 vision bilaterally. Fundoscopic exam showed no frank inflammation but did reveal a slightly raised subchoroidal white region directly under the anterior segment lesion. A scleral biopsy and scrape of an inferior subconjunctival lesion was performed of the right eye and sent for microbiology and histopathology. One day later, pathology STAT called the ophthalmology department with gram stain showing gram positive beaded branching rods suspicious for *Nocardia*. Histopathology returned showing reactive conjunctival epithelium overlying the sclera with associated granulation tissue and focal tissue breakdown consistent with early abscess formation. A presumptive diagnosis of infectious nodular scleritis was made. Prednisolone-acetate eye drops were discontinued while gatifloxacin and tobramycin were continued. The patient was started on sul-facetamide 10% eye drops every two hours (q2h), polymyxin-trimethoprim eye drops QID, oral TMP-SMX twice daily (BID), oral doxycycline, and vitamin C for anticollagenase activity twice daily. Culture results returned negative four days after cornea scraping and biopsy was performed.

The patient continued to complain of increasing pain in the eye. Six days after initial presentation, she underwent scleral debridement due to expanding necrotic tissue that was presumed to be acting as a nidus for further infection. At this time, the vision in the right eye had declined to 20/40. During surgery, it was noted that the entire inferior quadrant of the eye was ischemic and necrotic. A wide excision of the necrotic area was performed. Intravenous imipenem was given due to the presence of a very large area of exposed choroid. A pedicle graft consisting of conjunctiva and Tenon's capsule was used to cover the large area of exposed choroid. Imipenem 5 mg/mL drops were started every two hours. The patient continued to have significant pain and was taken back to the operating room one week later for further debride-ment as well as removal of a scleral abscess at the limbus. Cultures were drawn from this abscess during the procedure. Infectious disease was consulted and they recommended beginning amikacin due to anecdotal reports of efficacy in case series. Due to concern of invasive nocardiosis, parenteral imipenem was continued. Parenteral TMP-SMX was started to cover for possible resistance. Results returned five days later or three weeks after initial presentation with a diagnosis of *Nocardia asteroides*. Sensitivities of the *Nocardia* isolate showed resistance to TMP-SMX, sul-facetamide, clindamycin, and linezolid. It was sensitive to amikacin, azithromycin, and imipenem. All antibiotics were discontinued with the exception of imipenem IV every six hours (q6h), topical amikacin 2.5% q2h, and topical imipenem 5 mg/mL q2h.

The patient reported improved vision and pain over the following 5 days and she was discharged with a peripherally inserted central catheter in order to continue her antibiotic regimen. Her medications were discontinued after eight weeks upon significant improvement. On resolution of the infection, the patient was left with an area of scleral malacia in the inferonasal quadrant where the sclera had been debrided (Figure 2). No further treatment was planned as the area was thought to be healthy and well-vascularized. Her uncorrected vision was 20/70. Safety glasses were advised at all times for protection of this potentially weak area.

3. Discussion

The predisposing factors for infectious scleritis are numerous. Literature has reported scleritis associated with sclera buckle surgery, trauma, cataract surgery, combined penetrating keratoplasty, and steroids [5]. Hodson et al. report that a history of pterygium excision along with concomitant radiation or mitomycin C is the most common predisposing factor for infectious scleritis in the study population [6]. The patient in this report developed infectious scleritis following pterygium excision likely due to ischemia from cauteryization as well as nonhealing of the conjunctiva due to the concomitant use of Mitomycin C [7].

Our patient was initially treated with sulfacetamide eye drops, polymyxin-trimethoprim eye drops, and oral TMP-SMX based on recommendations from previous case reports. A frequently chosen option for ocular *Nocardia* infections is amikacin, likely due to its high susceptibility to the drug. Uhde et al. reported the resistance to amikacin to be as low as 5% [2]. Another treatment shown to be efficacious for nocardiosis is TMP-SMX, which has been specifically recommended in some reports [8–10]. When treating a case of refractory nocardiosis of the sclera, Decroos et al. endorse the use of linezolid due to the high susceptibility of *Nocardia* to the antimi-crobial [11]. In fact, the literature reports that *Nocardia* has a near 100% susceptibility to linezolid with respect to all species and strains [2–4].
We report the first case of a Nocardia scleritis with a strain that is resistant to linezolid. Multiple studies have yielded only a handful of Nocardia isolates resistant to the antimicrobial [4]. This strain was also resistant to TMP-SMX. This resistance to TMP-SMX is the second reported case of a Nocardia scleritis in the literature [12].

We also report the first treatment of a Nocardia scleritis using dual therapy of topical amikacin and intravenous imipenem. Imipenem is not usually the first line therapy for Nocardia as this organism has been shown to be resistant to imipenem in up to 30% of isolates [2]. However, Ameen et al. reported that both imipenem monotherapy and imipenem in combination with amikacin on Nocardia infections refractory to sulfonamides were very efficacious; all patients in the study obtained at least a 75% improvement of their infection [13]. However, the use of this drug is limited by its cost, need for intravenous administration, and significant toxicity [3].

This case also underscores the need for debridement of infectious and ischemic tissue in cases of infectious scleritis—especially those caused by infectious organisms that are difficult to medically treat such as Nocardia or fungus. In addition, mobilizing vascularized tissue to the ischemic area by means of a pedicle graft can assist in resolving the infectious process.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Dr. Tuli had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Tuli and Gonzalez were responsible for study concept and design. Tuli, Gubernick, and Fakhar were responsible for acquisition, analysis, or interpretation of data. Drafting of the paper was handled by Tuli and Gonzalez who critically revised the paper for important intellectual content and were responsible for administrative, technical, or material support. Tuli supervised the study.

References

[1] S. K. Sahu, S. Sharma, and S. Das, "Nocardia scleritis-clinical presentation and management: a report of three cases and review of literature," Journal of Ophthalmic Inflammation and Infection, vol. 2, no. 1, pp. 7–11, 2012.

[2] K. B. Uhde, S. Pathak, I. McCullum Jr. et al., "Antimicrobial-resistant Nocardia isolates, United States, 1995–2004," Clinical Infectious Diseases, vol. 51, no. 12, pp. 1445–1448, 2010.

[3] B. A. Brown-Elliott, S. C. Ward, C. J. Crist, L. B. Mann, R. W. Wilson, and R. J. Wallace Jr., "In vitro activities of linezolid against multiple Nocardia species," Antimicrobial Agents and Chemotherapy, vol. 45, no. 4, pp. 1295–1297, 2001.

[4] C.-C. Lai, W.-L. Liu, W.-C. Ko et al., "Antimicrobial-resistant Nocardia isolates, Taiwan, 1998–2009," Clinical Infectious Diseases, vol. 52, no. 6, pp. 833–835, 2011.

[5] H. Maruo, A. Shiraishi, Y. Hara, Y. Maruo, and Y. Ohashi, "Necrotizing nocardial scleritis successfully treated with surgical debridement and topical polyvinyl alcohol iodine and antibiotics," Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 4, pp. 415–418, 2011.

[6] K. L. Hodson, A. Galor, C. L. Karp et al., “Epidemiology and visual outcomes in patients with infectious scleritis,” Cornea, vol. 32, no. 4, pp. 466–472, 2013.

[7] E. R. Ramenaden and V. R. Raiji, “Clinical characteristics and visual outcomes in infectious scleritis: a review,” Clinical Ophthalmology, vol. 7, pp. 2113–2122, 2013.

[8] J. G. Brooks Jr., R. A. D. Mills, and D. J. Coster, “Nocardial scleritis,” American Journal of Ophthalmology, vol. 114, no. 3, pp. 371–372, 1992.

[9] H. M. Kattan and S. C. Pflugfelder, “Nocardia scleritis,” American Journal of Ophthalmology, vol. 110, no. 4, pp. 446–447, 1990.

[10] L. P. King, W. B. Furlong, W. S. Gilbert, and C. Levy, "Nocardia asteroides infection following scleral buckling," Ophthalmic Surgery, vol. 22, no. 3, pp. 150–152, 1991.

[11] F. C. Decroos, P. Garg, A. K. Reddy et al., “Optimizing diagnosis and management of Nocardia keratitis, scleritis, and endophthalmitis: 11-year microbial and clinical overview,” Ophthalmology, vol. 118, no. 6, pp. 1193–1200, 2011.

[12] S. Basti, U. Gopinathan, and S. Gupta, “Nocardial necrotizing scleritis after trauma: successful outcome using cefazolin,” Cornea, vol. 13, no. 3, pp. 274–276, 1994.

[13] M. Ameen, R. Arenas, E. V. del Mercado, R. Fernández, E. Torres, and R. Zacarias, "Efficacy of imipenem therapy for Nocardia actinomycetomas refractory to sulfonamides," Journal of the American Academy of Dermatology, vol. 62, no. 2, pp. 239–246, 2010.